(R)-tert-butyl 1-acetylpyrrolidin-3-ylcarbamate | 881298-14-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (R)-tert-butyl 1-acetylpyrrolidin-3-ylcarbamate
• 英文别名: tert-butyl 1-acetyl-3-pyrrolidinylcarbamate；1-Acetyl-3-(BOC-Amino)pyrrolidine；tert-butyl N-(1-acetylpyrrolidin-3-yl)carbamate
• CAS: 881298-14-2
• 化学式: C₁₁H₂₀N₂O₃
• mdl: MFCD24393040
• 分子量: 228.291
• InChiKey: LCOCMEGQRKOYAP-UHFFFAOYSA-N

物化性质

• 沸点：
  378.2±31.0 °C(Predicted)
• 密度：
  1.10±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.818
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Acetyl-3-(BOC-Amino)pyrrolidine
Synonyms: tert-Butyl N-(1-acetylpyrrolidin-3-yl)carbamate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Acetyl-3-(BOC-Amino)pyrrolidine
CAS number: 881298-14-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H20N2O3
Molecular weight: 228.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (R)-tert-butyl 1-acetylpyrrolidin-3-ylcarbamate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 14.0h， 生成 1-乙酰基-3-氨基吡咯烷
  参考文献：
  名称：

  Nicotinamide derivatives useful as PDE4 inhibitors

  摘要：

  这项发明涉及一般式（I）的烟酰胺衍生物：其中X、Y、n、Z、L和R具有本文中定义的含义，以及用于制备、制备中间体、含有和使用这种衍生物的过程。

  公开号：

  US20050020587A1
• 作为产物：
  描述：

  盐酸 、 3-(Boc-氨基)吡咯烷 、 乙酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 14.0h， 生成 (R)-tert-butyl 1-acetylpyrrolidin-3-ylcarbamate
  参考文献：
  名称：

  Nicotinamide derivatives useful as PDE4 inhibitors

  摘要：

  这项发明涉及一般式（I）的烟酰胺衍生物：其中X、Y、n、Z、L和R具有本文中定义的含义，以及用于制备、制备中间体、含有和使用这种衍生物的过程。

  公开号：

  US20050020587A1

文献信息

• APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
  申请人：Bruncko Milan

  公开号：US20100305122A1

  公开（公告）日：2010-12-02

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

  揭示了抑制抗凋亡Bcl-2蛋白活性的化合物，含有这些化合物的组合物以及治疗在其中表达抗凋亡Bcl-2蛋白的疾病的方法。
• [EN] TRICYCLIC HETEROCYCLES USEFUL AS TEAD BINDERS<br/>[FR] HÉTÉROCYCLES TRICYCLIQUES UTILES EN TANT QUE LIANTS TEAD
  申请人：MERCK PATENT GMBH

  公开号：WO2021224291A1

  公开（公告）日：2021-11-11

  The present invention relates to tricyclic heterocycles. These heterocyclic compounds are useful as TEAD binders and/or inhibitors of YAP-TEAD and TAZ-TEAD protein-protein interaction or binding and for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases, in particular cancer.

  本发明涉及三环杂环化合物。这些杂环化合物可用作TEAD结合物，和/或YAP-TEAD和TAZ-TEAD蛋白质间的相互作用或结合的抑制剂，用于预防和/或治疗包括过度增殖性疾病和疾病在内的多种医疗条件，特别是癌症。
• MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
  申请人：Birtalan Esther

  公开号：US20120108590A1

  公开（公告）日：2012-05-03

  A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of Formula I, the water-soluble polymeric carrier and the surfactant, to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; and cooling the resulting extrudate to to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer or an immune or autoimmune disease.

  一种促凋亡的固态分散物包括本文所定义的化合物I公式的Bcl-2家族蛋白抑制剂，以基本非结晶形式分散在固态基质中，该基质包括（a）药学上可接受的水溶性聚合物载体和（b）药学上可接受的表面活性剂。制备这种固态分散物的过程包括将公式I的化合物、水溶性聚合物载体和表面活性剂暴露于高温下，以提供可挤出的半固体混合物；挤出半固体混合物；并冷却所得到的挤出物，以提供包含聚合物载体和表面活性剂的固态基质，并在其中分散化合物的基本非结晶形式。这种固态分散物适用于口服给予需要治疗由一个或多个抗凋亡Bcl-2家族蛋白过度表达所特征的疾病的患者，例如癌症或免疫或自身免疫性疾病。
• APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
  申请人：Bruncko Milan

  公开号：US20110124628A1

  公开（公告）日：2011-05-26

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

  本发明涉及一种抑制抗凋亡Bcl-2蛋白活性的化合物，含有该化合物的组合物以及治疗表达抗凋亡Bcl-2蛋白的疾病的方法。
• [EN] SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT<br/>[FR] DISPERSIONS SOLIDES CONTENANT UN AGENT INDUISANT L'APOPTOSE
  申请人：ABBOTT LAB

  公开号：WO2012058392A1

  公开（公告）日：2012-05-03

  A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

  一种促凋亡的固体分散体包括本文所定义的化合物I的Bcl-2家族蛋白抑制剂，在基本非晶态形式下分散在固体基质中，该固体基质包括（a）一种药用可接受的水溶性聚合物载体和（b）一种药用可接受的表面活性剂。制备这种固体分散体的过程包括在适当的溶剂中溶解化合物、聚合物载体和表面活性剂，并去除溶剂，以提供包含聚合物载体和表面活性剂的固体基质，并在其中分散化合物的基本非晶态形式。该固体分散体适用于口服给予需要治疗一种或多种抗凋亡Bcl-2家族蛋白过度表达的疾病的受试者，例如癌症。